JaroslawJacMD

PubMed

• 14 citations
  Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC.
  Eng Huat Tan, Wan-Teck Lim, Myung-Ju Ahn, Quan Sing Ng, Jin Seok Ahn, Daniel Shao-Weng Tan, Jong-Mu Sun, May Han, Francis C. Payumo, Krista McKee, Wei Yin, Marc Credi,...> ;Clinical Pharmacology in Drug Development. 2018 Jan 18
• A phase II trial of chemotherapy plus hormone therapy as initial treatment of unresectable/metastatic adenocarcinoma of the prostate.
  Amato RJ, Jac J, Stepankiw M, Ramirez P> ;J. Clin. Oncol.. 2012-02-10
• 59 citations
  Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-...
  Robert J. Amato, William Shingler, Madusha Goonewardena, Jackie de Belin, Stuart Naylor, J. Jac, J. P. Willis, Somyata Saxena, Joan Hernandez-McClain, Richard Harrop> ;Journal of Immunotherapy. 2009 Sep 1
• 165 citations
  A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
  Robert J. Amato, J. Jac, Sarah Giessinger, Somyata Saxena, J. P. Willis> ;Cancer. 2009 Jun 1
• 44 citations
  Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered with Interleukin 2: A Phase II Trial
  Robert J. Amato, William Shingler, Stuart Naylor, J. Jac, J. P. Willis, Somyata Saxena, Joan Hernandez-McClain, Richard Harrop> ;Clinical Cancer Research. 2008 Nov 15
• 17 citations
  Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study results.
  Robert J. Amato, Jaroslaw Jac, Joan Hernandez-McClain> ;Clinical Genitourinary Cancer. 2008 Sep 1
• 44 citations
  Pilot study of rapamycin in patients with hormone-refractory prostate cancer.
  Robert J. Amato, J. Jac, Taqi Mohammad, Somya Saxena> ;Clinical Genitourinary Cancer. 2008 Sep 1
• 47 citations
  Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial.
  Robert J. Amato, Noel Drury, Stuart Naylor, J. Jac, Somya Saxena, Amy Cao, Joan Hernandez-McClain, Richard Harrop> ;Journal of Immunotherapy. 2008 Jul 1
• 7 citations
  Interferon-α in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: A phase II trial
  Robert J. Amato, J. Jac, Joan Hernandez-McClain> ;Anti-Cancer Drugs. 2008 Jun 1
• A phase I study with a daily regimen of the oral mTOR inhibitor RAD001 (Everolimus) plus sorafenib for patients with metastatic renal cell cancer (MRCC).
  Giessinger S, Amato RJ, Jac J, Saxena S, Willis JP, Chiang SB> ;J. Clin. Oncol.. 2008-05-20
• A phase I study of PEG-intron, sunitinib and tarceva in patients with metastatic renal cell cancer (MRCC).
  Vance V, Amato RJ, Jac J, Saxena S, Willis JP, Chiang SB> ;J. Clin. Oncol.. 2008-05-20
• A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine ...
  Jac J, Amato RJ, Giessinger S, Saxena S, Willis JP> ;J. Clin. Oncol.. 2008-05-20
• A phase II trial of intra-patient dose escalated-sorafenib in patients (pts) with metastatic renal cell cancer (MRCC).
  Amato RJ, Jac J, Harris P, Dalton M, Saxena S, Monzon F, Zhai J, Brady J, Willis JP> ;J. Clin. Oncol.. 2008-05-20
• Vaccination of renal cell cancer (RCC) patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax [T]) administered + low dose interleukin-2 (IL-2...
  Hernandez-McClain J, Amato RJ, Shingler WH, Naylor S, Jac J, Willis JP, Saxena S, Harrop R> ;J. Clin. Oncol.. 2008-05-20
• 6 citations
  Targeted anti-cancer therapies for renal cancer.
  Robert J. Amato, J. Jac> ;Drugs. 2006 Jan 1
• Rapamycin for androgen-independent prostrate cancer (AIPC).
  Sharef S, Jac J, Khan M, Amato RJ> ;J. Clin. Oncol.. 2006-06-20
• The treatment of primary and metastatic renal cell carcinoma (RCC) with stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS).
  Teh BS, Bloch C, Paulino AC, Doh L, Chiang S, Shen S, Baskin D, Jac J, Amato RJ> ;J. Clin. Oncol.. 2006-06-20
• Interferon-alpha (INF) and gefitinib or imatinib in patients (pts) with metastatic renal cell carcinoma (RCC).
  Jac J, Zhai Q, Kareidy M, Hernandez J, Marsh L, Amato RJ> ;J. Clin. Oncol.. 2006-06-20
• Phase II trial of motexafin gadolinium (MGd) for treatment of metastatic renal cell carcinoma (MRCC).
  Jac J, Hernandez J, Phan S, Amato RJ> ;J. Clin. Oncol.. 2005-06-01
• The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT).
  Teh, B., Bloch, C., Galli-Guevara, M., Doh, L., Richardson, S., Chiang, S., Yeh, P., Gonzalez, M., Lunn, W., Marco, R., Jac, J., Paulino, A., Lu, H., Butler, E., Amato...> ;Biomed Imaging Interv J. 2007 Jan
• Join now to see all